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Abstract
Alcohol use is a leading cause of preventable morbidity and mortality worldwide, with much of its 
negative impact as the result of alcoholic liver disease (ALD). ALD is a broad term that 
encompasses a spectrum of phenotypes ranging from simple steatosis to steatohepatitis, 
progressive fibrosis, cirrhosis, and hepatocellular carcinoma. The mechanisms underlying the 
development of these different disease stages are incompletely understood. Standard treatment of 
ALD, which includes abstinence, nutritional support, and corticosteroids, has not changed in the 
last 40 years despite continued poor outcomes. Novel therapies are therefore urgently needed. The 
development of such therapies has been hindered by inadequate resources for research and 
unsuitable animal models. However, recent developments in translational research have allowed 
for identification of new potential targets for therapy. These targets include: (i) CXC chemokines, 
(ii) IL-22/STAT3, (iii) TNF receptor superfamily, (iv) osteopontin, (v) gut microbiota and 
lipopolysaccharide (LPS), (vi) endocannabinoids, and (vii) inflammasomes. We review the natural 
history, risk factors, pathogenesis, and current treatments for ALD. We further discuss the findings 
of recent translational studies and potential therapeutic targets.
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Introduction
Alcohol consumption is a leading cause of global morbidity and mortality, with much of the 
burden resulting from alcoholic liver disease (ALD). Excessive alcohol intake can lead to 
liver damage through its direct action as a hepatotoxin1 as well as potentiation of other liver 
diseases including chronic viral hepatitis and non-alcoholic fatty liver disease (NAFLD).2–4
Despite the profound impact of ALD on public health, relatively few advances have been 
made in this field. The disease pathogenesis remains poorly understood, and medical 
© 2013 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd




J Gastroenterol Hepatol. Author manuscript; available in PMC 2015 April 21.
Published in final edited form as:













treatment for ALD has not changed significantly in 40 years.5 This situation is in marked 
contrast to the considerable advances in the treatment of other liver diseases such as viral 
hepatitis. Impediments to more robust progress in the field of ALD include inadequate 
experimental models of disease, a lack of interest from pharmaceutical companies, and 
inadequate public funding of ALD research.
Here, we review the natural history of ALD and its clinical and pathologic characteristics. 
We also describe the current understanding of pathogenic mechanisms underlying this 
disease as well as potential new therapeutic targets.
Natural history and risk factors
ALD is a broad designation that encompasses a range of disorders including simple 
steatosis, inflammation, fibrosis, and cirrhosis. Steatosis, which is present in more than 90% 
of heavy drinkers, is asymptomatic and reversible with abstinence. However, with continued 
alcohol intake, hepatic inflammation and injury can occur, a condition known as alcoholic 
hepatitis (AH). The prognosis of AH is variable, with nearly 100% survival in mild cases as 
compared to high short-term mortality among the most severe cases.6,7 Various predictive 
models have been developed to aid in the assessment of prognosis and to guide treatment, 
including Maddrey’s discriminant function, the model for end-stage liver disease (MELD), 
the Glasgow score, the ABIC score, and the Lille model.7–11
Patients with continued excessive alcohol consumption are at risk for the development of 
fibrosis and cirrhosis. Twenty to 40% of patients with steatosis will progress to fibrosis, of 
which 8–20% will develop cirrhosis.12,13 As in other liver diseases, patients with cirrhosis 
are at risk for hepatic decompensation (ascites, variceal bleeding, and encephalopathy) and 
hepatocellular carcinoma (HCC) (Fig. 1).
Although the most important risk factor for ALD is the absolute amount of alcohol intake, 
multiple other factors play a role in host susceptibility.14 Women are at greater risk of ALD, 
as are Mexican and black non-Hispanic Americans for reasons that are not well 
understood.15–17 Obesity may potentiate the hepatotoxic effects of alcohol, presumably 
through mechanisms similar to those that result in non-alcoholic steatohepatitis.18,19 
Smoking and the pattern of alcohol use are also associated with the increased risk of 
ALD.14,20,21
Genetic factors are also important in host susceptibility to ALD. Polymorphisms in the 
genes encoding NFκB subunits, interleukin (IL)-1β and IL-1 receptor antagonists, IL-2, 
IL-6, and IL-10 may modify ALD progression.22 Genetic variation in components of 
lipopolysaccharide (LPS)-induced intracellular pathways, such as CD14 and toll-like 
receptor (TLR) 4, may also be associated with ALD.23 Variations in PNPLA3, which 
encodes patatin-like phospholipase domain-containing protein 3, strongly and reproducibly 
influence the progression of ALD.24–26 To date, there are no large-scale, well-designed, 
genome-wide association studies for ALD. Such a study will be vital in advancing the field 
of ALD and identifying new targets for therapy.
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Steatosis is the first response of the liver to alcohol abuse. It is defined histologically as the 
deposition of fat in hepatocytes. Alcohol intake increases NADH/NAD+ in hepatocytes, 
thereby disrupting fatty acid oxidation and leading to steatosis development.27 It also 
increases fatty acid and triglyceride synthesis, enhances hepatic influx of free fatty acids 
from adipose tissue and chylomicrons from the intestinal mucosa, increases hepatic 
lipogenesis, decreases lipolysis, and damages mitochondria and microtubules, resulting in 
accumulation of very-low-density lipoprotein (VLDL).28–32
Alcohol upregulates lipogenic enzymes through upregulation of sterol regulatory element-
binding protein 1c (SREBP-1c)33 and downregulation of peroxisome proliferator-activated 
receptor (PPAR)-α.34,35 In addition, alcohol downregulates adenosine monophosphate-
activated protein kinase (AMPK). AMPK inactivates acetyl-CoA carboxylase, which, 
through its effects on malonyl-CoA and carnitine palmitoyltransferase 1, leads to reduced 
fatty acid synthesis and increased fatty acid oxidation, promoting steatosis.36,37
Steatohepatitis is characterized by steatosis, a superimposed inflammatory infiltrate of 
predominantly polymorphonuclear leukocytes and hepatocellular damage. In addition, 
biopsy specimens may show centrilobular hepatocyte ballooning, Mallory-Denk hyaline 
inclusions, and a “chicken wire”-like pattern of fibrosis.16 When the inflammation and 
hepatocellular injury are severe, the condition is termed AH.
The pathogenesis of AH is complex and multifactorial (Fig. 2). In the liver, alcohol is 
metabolized primarily into acetaldehyde, which binds proteins and DNA, forming adducts 
that promote glutathione depletion, lipid peroxidation, and mitochondrial damage.38,39 
These adducts also act as antigens that activate the adaptive immune response, leading to 
lymphocyte recruitment to the liver.40–42
Alcohol use also increases gut permeability and translocation of bacterial products such as 
LPS into the portal circulation.43 In Kupffer cells, LPS activates the MyD88-independent 
signaling pathway through TLR4, resulting in the production of proinflammatory cytokines 
such as tumor necrosis factor (TNF)-α that contribute to hepatocellular damage.44–47 
Interestingly, Kupffer cells also produce anti-inflammatory cytokines (IL-10) and 
hepatoprotective factors (IL-6) that reduce alcohol-induced hepatocellular damage.48–50 
This protective pathway may be an explanation for 70% of heavy drinkers not developing 
severe forms of alcoholic liver injury.
The presence of a neutrophilic infiltrate, a key feature of alcoholic steatohepatitis, is likely 
instigated by a host of proinflammatory cytokines. Acetaldehyde, LPS, TNF-α, palmitic 
acid, and downregulation of proteasome functions stimulate the production of these 
cytokines.51–53 IL-17, one of the implicated cytokines, directly induces neutrophil 
recruitment and also stimulates hepatic stellate cells (HSCs) to produce IL-8 and 
CXCL1.54–57 In turn, IL-8 and CXCL1 also promote recruitment of neutrophils. Additional 
cytokines and chemokines, such as TNF-α, IL-1, osteopontin, CXCL4, CXCL5, and 
CXCL6, are upregulated and may also contribute to neutrophil recruitment during alcoholic 
liver injury.
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Chronic alcohol use can result in fibrosis, which refers to the extracellular accumulation of 
collagen and other matrix proteins. Acetaldehyde plays a central role in fibrogenesis. It 
directly increases the expression of collagen in HSCs, and when combined with cellular 
components, produces various adducts that maintain HSC activation.58 HSCs can also be 
activated by neutrophils, damaged hepatocytes, and activated Kupffer cells through various 
pro-fibrogenic mediators including TGF-β, platelet-derived growth factor, IL-8, TNF-α, and 
reactive oxygen species (ROS).59,60 ROS decrease the action of metalloproteinases and up-
regulate tissue inhibitor of metalloproteinases 1, resulting in collagen accumulation.61 They 
also stimulate HSC pro-fibrogenic signaling pathways such as ERK1, ERK2, 
phosphoinositide 3 kinase-Akt, and c-Jun N-terminal kinase (JNK).62,63 LPS is also 
involved in fibrogenesis. LPS activates TLR4 signaling in HSCs and sinusoidal endothelial 
cells, resulting in HSC activation and promotion of fibrogenesis through regulation of 
angiogenesis.64,65
Finally, alcohol consumption inhibits the anti-fibrotic action of natural killer (NK) cells.66 
NK cells destroy activated HSCs and produce interferon (IFN)-γ which induces HSC cell 
cycle arrest and apoptosis.67–69 Such interference with the function of NK cells and IFN-γ 
may be an important component of both alcoholic fibrosis and alcohol promotion of fibrosis 
due to viral hepatitis.
Current treatment
Alcohol cessation is the mainstay of therapy for patients with all stages of ALD.70,71 In 
addition, abstinence is critical for patients who require liver transplantation because active 
alcohol use is, in general, a contraindication to transplant.72 Referral to formal rehabilitation 
programs is usually necessary to achieve abstinence. In addition, pharmacologic therapy 
with agents such as disulfiram, acamprosate, baclofen, and naltrexone can be considered, 
although their efficacy is limited.73–76 Patients with alcoholic cirrhosis should receive 
additional routine care such as screening and management of varices, screening for HCC, 
and vaccination for hepatitis A and B, among others.77
For severe AH, admission to the hospital is usually required. Patients should be assessed and 
closely monitored for alcohol withdrawal, encephalopathy, and bacterial infections, which 
are common in this patient group. Intensive nutritional support has been advocated, although 
its effect on patient outcomes is controversial.78,79
Corticosteroids have been the subject of numerous clinical trials since they were first 
introduced as a treatment for AH 40 years ago. Most have demonstrated a survival 
advantage when used in patients with severe disease, and current clinical practice guidelines 
recommend their use in patients with a Maddrey’s discriminant function ≥ 32 and those with 
hepatic encephalopathy.16,80,81 Pentoxifylline may also be useful in the treatment of severe 
AH, and is an alternative when corticosteroids are contraindicated.82 Pentoxifylline is not 
useful as a rescue agent in those who have not responded to corticosteroids, and the 
combination of these medications is not more effective than corticosteroids alone.83,84 N-
acetylcysteine may offer additional incremental benefit when combined with prednisolone.85
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Because of the implication of TNF-α in ALD pathogenesis and the benefit of pentoxifylline 
in AH, TNF-α antagonists have been studied for this condition. Early studies were 
promising, but larger clinical trials demonstrated an increased risk of infection and mortality 
with these agents.86–88 Another agent, S-adenosylmethionine (SAMe), has been shown to 
act as an antioxidant and downregulator of TNF-α, and therefore may be protective against 
ALD.89 Currently, however, clinical data are inconclusive, and further study of this agent is 
needed.90 Studies of other medications, such as anabolic steroids, vitamin E, silibinin, 
colchicine, and propylthiouracil, have likewise been disappointing.91–95
Liver transplantation is an option for patients with end-stage liver disease due to alcohol, 
with favorable post-transplant outcomes compared to transplantation for other indications.96 
Because of concerns about recidivism and the potential for clinical improvement with 
alcohol cessation, current guidelines recommend a period of abstinence prior to considering 
transplant, in accordance with the practice patterns of the majority of transplant centers.97 
This policy essentially excludes patients with severe AH, who, by definition, have not had a 
period of abstinence. Recently published data suggest that liver transplant may be 
considered for highly selected patients who have not responded to standard therapies.98 
These results call into question the requirement for a strictly defined period of 
abstinence.72,99
New targets for therapy
Ideally, new treatments for ALD should be effective, safe, and selective. The development 
of such agents requires the identification of molecular targets specific for ALD. As animal 
models do not accurately mimic advanced ALD, and the pathophysiologic significance of 
serum levels of biomarkers is unclear (due to impaired liver clearance and ongoing bacterial 
infections), liver tissue from patients with ALD may serve as a source to identify therapeutic 
targets (Fig. 3). Here, we discuss the most promising targets for ALD identified in human 
samples.
CXC chemokines
Members of the CXC family of chemokines include interleukin 8 (IL-8) and growth-
regulated α-protein (Gro-α). These mediators attract polymorphonuclear leukocytes, which 
are the predominant inflammatory cells that infiltrate the livers of patients with ALD. In 
patients with AH, expression of these chemokines in the liver correlates with the severity of 
portal hypertension and patient survival.56,100
IL-22/STAT3 pathway
Interleukin 22 (IL-22), a member of the interleukin 10 (IL-10) family of cytokines, is 
important in controlling bacterial infection, homeostasis, and tissue repair. Through 
activation of the signal transducer and activator of transcription 3 (STAT3), it has been 
shown to improve ALD in rodent models.101 Furthermore, IL-22 expression is decreased, 
whereas IL-22 receptor 1 expression is upregulated in patients with ALD. Because of its 
antibacterial properties, it may be an ideal therapy in combination with corticosteroids, 
which predispose to bacterial infections.
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Tumor necrosis factor α (TNF-α) is not overexpressed in the livers of patients with AH. 
However, fibroblast growth factor inducible 14 (Fn14), a member of the TNF receptor 
superfamily (member 12A) is overexpressed in these patients.102 Moreover, its expression 
correlates with disease severity. This receptor is expressed primarily in hepatic progenitor 
cells, which accumulate in patients with severe AH.
Osteopontin
Osteopontin, an extracellular matrix protein, is upregulated in the livers of patients with 
ALD, and its expression correlates with disease severity.103 Animals that lack osteopontin 
are relatively protected from alcohol-mediated liver damage as well.104 Inhibition of 
osteopontin-mediated pathways may therefore be an effective therapy for ALD.
Gut microbiota and LPS
Alterations in the gut micro-biome and increased gut permeability associated with ALD can 
result in increased LPS in the portal circulation. Rifaximin, a nonabsorbable antibiotic that 
alters the gut microbiota, is efficacious in the treatment of hepatic encephalopathy, and 
could have a role in ALD.105 Inhibition of LPS-induced TLR4 signaling has been suggested 
as another target for novel therapies.106
Endocannabinoids
Endocannabinoids are involved in the pathogenesis of ALD through cannabinoid receptors 1 
and 2 (CB1 and CB2).107 Animals lacking cannabinoid receptors have differential responses 
to alcohol-induced liver injury,108,109 suggesting the potential use of CB1 antagonists and 
CB2 agonists as therapeutic agents. Although CB1 antagonists are limited by their 
neuropsychiatric side effects, peripherally restricted agents may benefit patients with 
ALD.107
Inflammasome
Inflammasomes are intracellular multiprotein complexes that mediate the response to 
cellular danger signals activating and recruiting inflammatory cells. Inflammasome 
activation leads to activation of caspase-1, resulting in the release of IL-1β and IL-18.110 
Serum levels of IL-1β were found to be increased in patients with ALD as well as in animal 
models.111,112 Recent studies demonstrated mRNA expression of several inflammasomes in 
the liver thus suggesting that inflammasome activation is a component of the liver 
pathophysiology in ALD.113
Conclusions
Alcohol consumption is a leading cause of global morbidity and mortality, with much of its 
negative impact as a result of ALD. Despite some advances in our understanding of the 
pathogenesis and clinical characteristics of ALD, many questions remain. Standardized 
nomenclature and histologic classifications are lacking, and there have been no significant 
advances in therapy in the last 40 years. Recent translational work using human liver tissue 
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has been informative in identifying some potential therapeutic targets for this disease. 
However, translation of these findings into novel therapies has been lacking. Additional 
detailed studies of these potential targets in humans and animal models are urgently needed 
to improve outcomes in this patient population.
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Natural history of alcoholic liver disease and modifier factors. More than 80–90% of heavy 
drinkers develop fatty liver, but only up to 20–40% of this population develops more severe 
forms of alcoholic liver disease (ALD), including fibrosis, alcoholic hepatitis, cirrhosis, and 
hepatocarcinoma (HCC). Multiple other risk factors have been proposed to play a role in 
susceptibility to severe forms of ALD. HBV, hepatitis B virus; HCC, hepatocellular 
carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus.
Orman et al. Page 13














Pathogenic mechanisms of alcoholic liver disease proposed based in animal models 
evidence. Ethanol promotes the translocation of lipopolysaccharide from the gastrointestinal 
lumen to the portal vein, where it binds to the lipopolysaccharide-binding protein. In 
Kupffer cells, lipopolysaccharide binds to CD14, which combines with TLR4 activating 
multiple cytokine genes. The increase on inflammatory cytokine production in conjunction 
with a decrease in STATs expression reduces liver regeneration. Long-term alcohol 
consumption alters the intracellular balance of antioxidants with subsequent decrease in the 
release of mitochondrial cytochrome c and expression of Fas ligand, leading to hepatic 
apoptosis. Activated Kupffer cells and hepatocytes are suggested to be sources of free 
radicals (especially ROS), which are responsible for lipid peroxidation and further apoptotic 
damage. Activation of hepatic stellate cells also contributes to the production of cytokines, 
ROS and TGF-β exacerbating liver fibrosis. ADH, alcohol dehydrogenase; ALDH, aldehyde 
dehydrogenase; CD14, CYP2E1, cytochrome P450 2E1; HSC, hepatic stellate cells; LPS, 
lipopolysaccharide; NADPH, nicotinamide adenine dinucleotide phosphate; NFκB, nuclear 
factor κB; ROS, reactive oxygen species; STAT, signal transducer and activator of 
transcription; TGF-β, transforming growth factor β; TLR4, Toll-like receptor 4.
Orman et al. Page 14














Potential therapeutic targets for alcoholic liver disease identified in translational studies. The 
expression and/or activation of different mediators of alcoholic liver disease in liver tissue 
from patients have been investigated. These findings have been correlated with disease 
severity and the patient’s outcome. These targets include: CXC chemokines, IL-22/STAT3, 
TNF receptor superfamily, osteopontin, gut microbiota and LPS, endocannabinoids and 
inflammasomes. CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; Gro-α growth-
regulated α-protein; IL-8, interleukin 8; IL-22, interleukin 22; LPS, lipopolysaccharide; 
STAT3, signal transducer and activator of transcription 3; TNF, tumor necrosis factor; 
TLRs, toll-like receptors.
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